Pending AI
The AI engine Fit Assessment
BetaPending.AI effectively utilizes machine learning to enhance drug discovery, pattern discovery, and the development of new therapeutics.
Blurb
HQ Location
Founded
Employees
Total funding raised
Last Funding Event
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
- Drug Discovery Optimization
Founded by Professor Mark Waller, Pending AI has developed a comprehensive discovery platform enabled by artificial intelligence and quantum mechanics, ushering in a new paradigm of medicinal innovation where higher-quality small molecule drugs can be developed in a fraction of the time and cost. With operational presences across both Cambridge, Massachusetts, United States and Eveleigh, New South Wales, Australia, Pending AI is actively seeking research-and-development partnerships with pharmaceutical companies, as well as to ascertain interest from investors in the company's upcoming investment round.